454 Revenues Pick Up in Q3, But Roche's Overall Genomic Sales Decline 12 Percent Year to Date | GenomeWeb

By Julia Karow

This story was originally published Oct. 17.

Revenues of Roche's 454 Life Sciences unit increased in the third quarter compared to the second, while sales for Roche Applied Science's genomic analysis business, which comprises both 454 and Roche NimbleGen, declined 12 percent in local currencies during the first nine months of 2011.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.